Clonazepam tablets prescription in Santa Clara municipality
Abstract
Introduction: Benzodiazepines are drugs used for anxiety and sleep disorders, as well as muscle relaxants and anticonvulsive. Despite being discouraged in prolonged treatments, some patients have chronic use, which is associated with the development of physical dependence, manifested in moderate to severe withdrawal symptoms. Clonazepam is one such benzodiazepine which has antiepileptic as well as anxiolytic properties.
Objective: To determine the increase in prescription of clonazepam 1mg tablets in Santa Clara municipality.
Methods: An observational, retrospective, descriptive and cross-sectional investigation was carried out, which corresponded with a medications use study, of prescription-indication type. It was conducted aimed at assessing the prescription of the medication clonazepam 1mg tablets during the period from June 2021 to June 2023. The universe was built by 5819 patients which constituted the totality of ambulatory patients with such prescription at the end of the study.
Results: Regarding sex, at the end of the study, the distribution showed a predominance of the female sex. It was evidenced an increase of 198 % of patients and a predominance of patients over 59 years of age (55.33 %).
Conclusions: The results showed a high trend in the use of clonazepam, mainly in elderly patients, which are the most susceptible to the appearance of undesirable effects and unfortunate consequences.
DeCS: CLONAZEPAM; BENZODIAZEPINES; PRESCRIPTION DRUGS; SUBSTANCE-RELATED DISORDERS; HEALTH OF THE ELDERLY.
Downloads
References
1. Marín GH, del Mauro J, Marín L, Urtasun MA, Marín G, Nucher D, et al. Consumo de benzodiacepinas y fármacos Z en una organización de la seguridad social nacional argentina: ¿uso racional o excesivo? Salud Colect [Internet]. 2021 [citado 18 Jul 2023]; 17: e3583. Disponible en: https://www.scielosp.org/pdf/scol/2021.v17/e3583/es
2. World Health Organization. Programme on substance abuse: Rational use of benzodiazepines [Internet]. Copenhagen: WHO; 1996 [citado 16 Jul 2023]. Disponible en: https://iris.who.int/bitstream/handle/10665/65947/WHO_PSA_96.11.pdf?sequence=1&isAllowed=y
3. He Q, Chen X, Wu T, Li L, Fei X. Risk of dementia in long-term benzodiazepine users: evidence from a meta-analysis of observational studies. J Clin Neurol [Internet]. 2019 Ene [citado 16 Jul 2023];15(1):9-19. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325366/
4. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology [Internet]. Geneva: WHO; 2020 [citado 05 Ago 2023]. Disponible en: https://apps.who.int/whocc/Detail.aspx?Y4LL80197gk3R/zebVRpCw
5. Zorzanelli RT, Giordani F, Guaraldo L, Matos GC, Brito Junior AG, Goncalves de Oliveira M, et al. Consumption of the benzodiazepine clonazepam (Rivotril®) in Rio de Janeiro State, Brazil, 2009-2013: an ecological study. Ciência & Saúde Coletiva [Internet]. 2019 [citado 11 Jul 2023];24(8):3129-40. Disponible en: https://www.scielo.br/j/csc/a/SFJrxL764mB9KJSGHNfvBBk/?lang=en&format=pdf
6. Kurko T, Saastamoinen LK, Tuulio-Henriksson A, Taiminen T, Tiihonen J, Airaksinen M, et al. Trends in the long-term use of benzodiazepine anxiolytics and hypnotics: a national register study for 2006 to 2014. Pharmacoepidemiol Drug Saf [Internet]. 2018 Jun [citado 28 Jul 2023];27(6):674-82. Disponible en: https://onlinelibrary.wiley.com/doi/10.1002/pds.4551
7. American Geriatrics Society. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. JAGS [Internet]. 2019 [citado 02 Ago 2023];67(4):674-98. Disponible en: https://www.synprefh.org/files/file/formation/dpc/beers_criteria_updated_2019_list.pdf
8. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment): Consensus validation. Int J Clin Pharmacol Ther [Internet]. 2008 [citado 12 Ago 2023];46(2):72-83. Disponible en: https://www.optimage-poctefa.com/sites/optimagepoctefa.com/files/upload/Formation/stop%20start%20criteria%202008.pdf
9. Rodríguez Carranza R. Vademecum Académico de Medicamentos. 6ª ed [Internet]. México D.F: McGraw-Hill Interamericana; 2013 [citado 18 Nov 2023]. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?bookid=1552§ionid=90368752
10. Domínguez V, Collares M, Ormaechea G, Tamosiunas G. Uso racional de benzodiazepinas: hacia una mejor prescripción. Rev Urug Med Interna [Internet]. 2016 Dic [citado 11 Ago 2023];1(3). Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S2393-67972016000300002
11. Barboza L, Artagaveytia P, Speranza N, Domínguez V, Tamosiunas G. Segundo estudio de consumo de benzodiazepinas en una población uruguaya (2014-2018): el problema avanza. Rev Méd Urug [Internet]. 2022 [citado 10 Ago 2023];38(2):e38203. Disponible en: http://www.scielo.edu.uy/pdf/rmu/v38n2/1688-0390-rmu-38-02-e202.pdf
12. Fundación FEMEBA. Benzodiazepinas: Uso crónico y desprescripción. Folia Doc [Internet]. 2020 [citado 10 Ago 2023];XXIII(2). Disponible en: https://www.areadesaludmerida.es/wp-content/uploads/2022/02/1.Benzodiazepinas_-uso-cro%CC%81nico-y-desprescripcio%CC%81n.-2020.pdf
13. Ng BJ, Le Couter DG, Hilmer SN. Deprescribing benzodiazepines in older patients: impact of interventions targeting physicians, pharmacists, and patients. Drugs Aging [Internet]. 2018 Jun [citado 08 Ago 2023];35(6):493-521. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29705831/
14. Urtasun MA, Noble M, Cañas M, Bustin J, Regueiro AJ, Triskier F, et al. Uso de benzodiacepinas y fármacos relacionados en el seguro social para adultos mayores de Argentina. Medicina [Internet]. 2022 Ago [citado 10 Ago 2023];82(3). Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802022000500389
15. Davies SJC, Jacob B, Rudoler D, Zaheer J, de Oliveira C, Kurdyak P. Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013. Ther Adv Psychopharmacol [Internet]. 2018 Mar [citado 07 Ago 2023];8(3):99-114. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802639/
16. Brandt J, Alessi-Severini S, Singer A, Leong C. Novel Measures of Benzodiazepine and Z-Drug Utilisation Trends in a Canadian Provincial Adult Population (2001-2016). J Ther Popul Pharamcologie Clin. 2019 Ene;26(1):e22-e38. doi: 10.22374/1710-6222.26.1.3.
17. Wingard L, Taipale H, Reutfors J, Westerlund A, Bodén R, Tiihonen J, et al. Initiation and long-term use of benzodiazepines and Z-drugs in bipolar disorder. Bipolar Disord [Internet]. 2018 Nov [citado 04 Ago 2023];20(7):634-46. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1111/bdi.12626
18. Morin CM, Inoue Y, Kushida C, Poyares D, Winkelman J. Endorsement of European guideline for the diagnosis and treatment of insomnia by the World Sleep Society. Sleep Med [Internet]. 2021 May [citado 02 Ago 2023];81:124-6. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S138994572100040X?via%3Dihub
19. De Crescenzo F, D’Alò GL, Ostinell EG, Ciabattini M, Di Franco V, Watanabe N, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet [Internet]. 2022 [citado 06 Ago 2023];400:170-84. Disponible en: https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(22)00878-9.pdf
20. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing [Internet]. 2015 Mar [citado 04 Ago 2023];44(2):213-8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339726/
21. Villén Romero N, Troncoso Mariño A. Com I Quan Cal Fer Una Reducció Gradual de la Dosi Dels Medicaments? Butlletí Informació Terapèutica [Internet]. 2015 [citado 09 Ago 2023];26(7). Disponible en: https://scientiasalut.gencat.cat/bitstream/handle/11351/1870/BIT_2015_26_07_ca.pdf?sequence=1&isAllowed=y
Published
How to Cite
Issue
Section
License
Copyright: Camagüey Medical Archive Magazine, offers immediately after being indexed in the SciELO Project; Open access to the full text of the articles under the principle of making available and free the research to promote the exchange of global knowledge and contribute to a greater extension, publication, evaluation and extensive use of the articles that can be used without purpose As long as reference is made to the primary source.
Conflicts of interest: authors must declare in a mandatory manner the presence or not of conflicts of interest in relation to the investigation presented.
(Download Statement of potential conflicts of interest)
The Revista Archivo Médico de Camagüey is under a License Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 International (CC BY 4.0).
This license allows others to distribute, to mix, to adjust and to build from its work, even for commercial purposes, as long as it is recognized the authorship of the original creation. This is the most helpful license offered. Recommended for maximum dissemination and use of licensed materials. The full license can be found at: https://creativecommons.org/licenses/
22 julio 2025